Sunshine Heart has submitted an investigational device exemption (IDE) application of its C-Pulse Heart Assist system to the US Food and Drug Administration (FDA) for approval. The basis of the IDE application is for the initiation of ...
Tags: FDA, medical system, medical technology
Symantec today announced upgrades to its enterprise-class NetBackup software to focus on tighter integration with VMware and the ability to backup and recover virtual machines (VMs) more quickly. NetBackup 7.6 will include NetBackup ...
Tags: NetBackup 7.6, VMware, NetBackup software, VMs
Trend Micro has updated its mobile security software to detect potential attacks on several Samsung Electronics devices that have a flaw that could allow a malicious application to access all of the phone's memory. The company's Mobile ...
Tags: Trend Micro, mobile security software, Samsung Electronics devices
Sorin Group, a manufacturer of medical technologies for cardiac surgery, has purchased Neurotech to expand its market of neuromodulation therapies for treating heart failure. Neurotech's commercial products include implantable medical ...
Tags: cardiac surgery, medical technology, expansion, medical device
Sunshine Heart is planning to initiate a US pivotal trial on its C-Pulse Heart Assist device in the fourth quarter of 2012, as it received an unconditional approval from the US Food Drug Administration (FDA). The CE marked system, ...
Tags: FDA, clinical trial, medical system
The China Compulsory Certificate mark, commonly known as CCC Mark, is a compulsory safety mark for many products imported, sold or used in the Chinese market. It became implemented on May 1, 2002 and fully effective on August 1, 2003. It ...
Tags: CCC Mark, certification
Storage specialist, Seagate, today launched its Backup Plus selection of external hard drives in Dubai during a presentation on the future of storage and backup protection. Vice President of Sales and Marketing, Mark Whitby, held the ...
Tags: External hard drives, Hard drives, Seagate, physical hard drive
Intel this week presented an array of arguments to the E.U. General Court in its appeal of a massive 1.06 billion euros (US$1.33 billion) fine imposed by Europe's antitrust regulators. In 2009, the European Commission fined Intel for ...
CardioKinetix has reported positive three-year clinical data of its minimally invasive Parachute ventricular partitioning device, following Percutaneous Ventricular Restoration therapy in heart failure patients. The Parachute device, ...
Tags: CardioKinetix, clinical data, Parachute, ventricular partitioning device
The Treasury Committee requested that RBS chief executive Stephen Hester provide a detailed explanation of what went wrong at the bank to cause its ongoing IT issues. In a letter to the bank, Andrew Tyrie, chairman of the Treasury ...
Tags: RBS, MPs, IT Explanation
Atop the new investigation into Microsoft's failure to give some Windows users a browser ballot screen, European Union (EU) antitrust officials are also looking into charges that Microsoft has blocked rival browser makers from harnessing ...
Tags: EU, Microsoft, browser makers, Windows 8
In the face of an Apple demand for a sales ban on its Android products, Samsung told a Dutch court on Friday that in fact it has already changed the products so they no longer infringe. But the South Korean company's failure to provide ...
Tags: Apple, Android products, Samsung, Dutch court
Medtronic has gained CE mark for its Viva/Brava portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices. The family of CRT-Ds features a new algorithm, called AdaptivCRT, which by preserving patients' normal ...
Tags: Medtronic, CE mark, CRT-D devices, AdaptivCRT, CRT treatment
Biotronik is set to showcase its magnetic resonance imaging (MRI) approved implantable heart failure devices at the European Society of Cardiology congress, being held between 25-29 August 2012. The MRI-approved devices include Lumax 740 ...
Tags: Biotronik, MRI, heart failure devices, MRI-approved devices, CRT-D, CRT-P
CardioKinetix has started enrolling patients for its PARACHUTE III, a post-market safety surveillance trial, in Germany. The dual-arm, multi-center, open-label trial, which will enroll up to 100 ischemic heart failure patients, is ...